Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 7/2011

01-07-2011 | Letter

Laparoscopic and robotic-assisted D2 surgery for gastric cancer: a reality in Europe?

Author: Christof Hottenrott

Published in: Surgical Endoscopy | Issue 7/2011

Login to get access

Excerpt

The high rate of early gastric cancer (EGC) diagnosis, approximately 50% of all cases, in Japan and Korea has resulted in the rapid development, validation, and standardization of minimally invasive surgery for the treatment of early disease. Rigorous criteria have been established by the Japanese Association for Gastric Cancer for decision-making on endoscopic submucosal dissection (ESD) and laparoscopic surgery. Technical advances have revolutionized surgical oncology during the past two decades [1]. …
Literature
1.
Choh MS, Madura JA 2nd (2009) The role of minimally invasive treatments in surgical oncology. Surg Clin North Am 89(1):53–77PubMedCrossRef
2.
Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406PubMedCrossRef
3.
Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350PubMedCrossRef
4.
Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651PubMedCrossRef
5.
Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555PubMedCrossRef
6.
Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10(4):473–476PubMedCrossRef
7.
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11(5):439–449PubMedCrossRef
8.
Pugliese R, Maggioni D, Sansonna F, Costanzi A, Ferrari GC, Di Lernia S, Magistro C, De Martini P, Pugliese F (2010) Subtotal gastrectomy with D2 dissection by minimally invasive surgery for distal adenocarcinoma of the stomach: results and 5-year survival. Surg Endosc 24(10):2594–2602PubMedCrossRef
9.
Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRef
10.
Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043PubMedCrossRef
11.
Roukos DH, Ziogas DE, Katsios C (2010) Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. Expert Rev Anticancer Ther 10(8):1187–1195PubMedCrossRef
12.
Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586PubMedCrossRef
13.
Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRef
14.
Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287PubMedCrossRef
15.
Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48PubMedCrossRef
16.
Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995 author reply 1995–1996PubMedCrossRef
17.
Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681PubMedCrossRef
18.
Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782PubMedCrossRef
19.
Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Pers Med 7(4):347–350CrossRef
20.
Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128PubMedCrossRef
21.
Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416PubMedCrossRef
22.
Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068PubMedCrossRef
23.
Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361PubMedCrossRef
24.
Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250PubMedCrossRef
25.
Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362; author reply 1363
26.
27.
28.
Roukos DH (2011) Innovation versus evidence: to trust direct-to-consumer personal genomic tests? Expert Rev Mol Diagn 11(1):1–4 PubMedCrossRef
29.
Katsios C, Ziogas DE, Roukos DH (2011) New molecular oncology-changing era: prospects and challenges of cancer genome and integrative systems biology. Expert Rev Anticancer Ther 11(1):5–8PubMedCrossRef
Metadata
Title
Laparoscopic and robotic-assisted D2 surgery for gastric cancer: a reality in Europe?
Author
Christof Hottenrott
Publication date
01-07-2011
Publisher
Springer-Verlag
Published in
Surgical Endoscopy / Issue 7/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-010-1547-3

Other articles of this Issue 7/2011

Surgical Endoscopy 7/2011 Go to the issue

OriginalPaper

Laparoendoscopic single-site (LESS) surgery versus conventional laparoscopic surgery: comparison of surgical port performance in a surgical simulator with novices

New Technology

A novel endoscopic fluorescent clip for the localization of gastrointestinal tumors

OriginalPaper

Will the Playstation generation become better endoscopic surgeons?

OriginalPaper

Endoscopic stenting versus surgical colostomy for the management of malignant colonic obstruction: comparison of hospital costs and clinical outcomes

OriginalPaper

Bacterial clearance of biologic grafts used in hernia repair: an experimental study

Technique

Transumbilical single-incision laparoscopic distal gastrectomy for early gastric cancer